UK markets close in 3 hours 6 minutes

Xeris Pharmaceuticals, Inc. (XERS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.75000.0000 (0.00%)
At close: 04:00PM EDT
1.8200 +0.07 (+4.00%)
Pre-market: 08:00AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.7500
Open1.7400
Bid1.7400 x 800
Ask1.7700 x 800
Day's range1.7300 - 1.8300
52-week range1.4600 - 3.2600
Volume1,287,778
Avg. volume1,884,547
Market cap259.444M
Beta (5Y monthly)1.11
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024

    CHICAGO, May 02, 2024--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2024 financial results before the open of the U.S. financial markets on Thursday, May 9, 2024. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Comp

  • Business Wire

    Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    CHICAGO, April 03, 2024--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on April 1, 2024, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 103,000 shares of its common stock to 18 new employee(s) under Xeris’ Inducement Equity Plan.

  • Business Wire

    Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference

    CHICAGO, April 02, 2024--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris’ Chairman and CEO, will present an overview of the Company at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024 at 11:00 am Eastern Time. To access the presentation, please visit "Events" on